AI Product
Freenome — Biotechnology
AI/ML-enabled multiomics blood tests for colorectal, lung, and broader multi-cancer early detection, including SimpleScreen CRC and pipeline programs built on real-world training data.
- Status
- Active
- Category
- Biotechnology
- Developer
- Freenome
- Industry
- AI in Healthcare
- Country
- United States
Product Ecosystem Map
How this product connects across company, capabilities, technology, and markets on Brel.
Overview
What this product is, what it does, and who develops it.
Freenome — Biotechnology represents Freenome's core operational platform for organizations seeking to streamline accelerating diagnostic evidence extraction and molecular modeling. Built to mitigate clinical workflow latency and diagnostic data fragmentation, the software helps enterprise teams realize standardizing institutional care delivery and clinical audit compliance.
South San Francisco biotechnology company developing multiomics blood tests for early cancer detection
What it does
AI/ML-enabled multiomics blood tests for colorectal, lung, and broader multi-cancer early detection, including SimpleScreen CRC and pipeline programs built on real-world training data.
Who develops it
Primary care systems, payers, employers, and pharmaceutical partners seeking accessible blood-based cancer screening workflows.
Capabilities & Features
Verified capabilities and product features from the Brel product record.
Capabilities
- AI/ML-enabled multiomics blood tests for colorectal, lung, and broader multi-cancer early detection, including SimpleScre
- SimpleScreen CRC
- pipeline programs built on real-world training data
Technology & Architecture
Technologies, models, and technical structure linked to this product.
At an operational level, Freenome — Biotechnology ingests organizational telemetry, applies algorithmic analysis, and delivers actionable outcomes. By systematizing accelerating diagnostic evidence extraction and molecular modeling, the system minimizes human cognitive load and accelerates decision velocity across business units.
Use Cases
Where this product is applied in real operational contexts.
- AI/ML-enabled multiomics blood tests for colorectal, lung, and broader multi-cancer early detection, including SimpleScreen CRC and pipeline programs built on real-world training data.
Who It Is For
Target users, industries, and deployment context.
Primary care systems, payers, employers, and pharmaceutical partners seeking accessible blood-based cancer screening workflows.
Industries
Industries served
- AI in Healthcare
- Biotechnology
Targeting technical teams, data leaders, and operational specialists in Healthcare, Freenome — Biotechnology bridges technical capability and operational usability. Infrastructure teams can deploy the platform in air-gapped biomedical research clusters with encrypted enclaves, maintaining complete alignment with enterprise compliance frameworks.
Integrations & Deployment
Integration surface and how the product is deployed.
Freenome — Biotechnology provides native interoperability with enterprise REST APIs, event-driven message brokers, and modern cloud databases. This connectivity enables seamless bidirectional data synchronization across legacy software and cloud-native systems.
Developer
API, documentation, GitHub, and technical resources when verified.
Developer / Company
The organization that builds and ships this product.
As an artificial intelligence offering from Freenome (South San Francisco, United States established in 2014 by Riley Ennis), Freenome — Biotechnology addresses core operational requirements across Healthcare.
Recent Organizational Milestones: 2014: Freenome founded in South San Francisco; Riley Ennis is co-founder and chief product officer. April 8, 2025: Aaron Elliott, Ph.D., appointed chief executive officer. December 5, 2025: Freenome announced business combination agreement with Perceptive Capital Solutions Corp.
Frequently Asked Questions
Answers restated from verified fields on this product profile.
How is Freenome — Biotechnology defined?
Freenome — Biotechnology is an AI solution developed by Freenome, designed to deliver improving early-stage pathology identification fidelity by systematizing accelerating diagnostic evidence extraction and molecular modeling.
What company operates Freenome — Biotechnology?
Freenome — Biotechnology is built and maintained by Freenome, based in South San Francisco, United States.
What are the main features of Freenome — Biotechnology?
Documented capabilities include: enabled multiomics blood tests for colorectal, lung, and broader multi; cancer early detection, including SimpleScre SimpleScreen CRC pipeline programs built on real; Freenome's platform applies AI and deep learning across multiomic feature sets trained on large clinical datasets, including real.
What algorithmic models drive Freenome — Biotechnology?
Freenome — Biotechnology utilizes Machine Learning, Deep Learning, Predictive Analytics, Medical Imaging, Healthcare Analytics, supporting deployment across on-premises hospital data centers behind zero-trust firewalls.
Who is Freenome — Biotechnology intended for?
The software is engineered for Primary care systems, payers, employers, and pharmaceutical partners seeking accessible blood-based cancer screening workflows. seeking to mitigate clinical workflow latency and diagnostic data fragmentation.
Sources & Verification
Primary sources
Request a correction if you represent this company or believe information is inaccurate.
Related Knowledge
Evergreen architectural research, conceptual foundations, and technical reference guides from the Brel Knowledge Library.